Corbus Pharmaceuticals (NASDAQ:CRBP) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Corbus Pharmaceuticals (NASDAQ:CRBPGet Rating) in a research report issued to clients and investors on Tuesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Separately, Zacks Investment Research downgraded shares of Corbus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, May 10th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $1.83.

Corbus Pharmaceuticals stock opened at $0.31 on Tuesday. The business has a 50 day moving average of $0.38 and a 200-day moving average of $0.52. Corbus Pharmaceuticals has a 1 year low of $0.21 and a 1 year high of $2.29. The company has a debt-to-equity ratio of 0.22, a current ratio of 5.85 and a quick ratio of 5.85. The company has a market capitalization of $39.33 million, a P/E ratio of -0.95 and a beta of 2.03.

Corbus Pharmaceuticals (NASDAQ:CRBPGet Rating) last released its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.01. Corbus Pharmaceuticals had a negative return on equity of 54.78% and a negative net margin of 2,856.56%. Equities analysts anticipate that Corbus Pharmaceuticals will post -0.24 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in the business. ETF Managers Group LLC increased its position in Corbus Pharmaceuticals by 0.3% during the 4th quarter. ETF Managers Group LLC now owns 14,138,998 shares of the biopharmaceutical company’s stock valued at $8,534,000 after purchasing an additional 37,487 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Corbus Pharmaceuticals by 1.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,070,006 shares of the biopharmaceutical company’s stock worth $2,506,000 after buying an additional 69,769 shares in the last quarter. Morgan Stanley boosted its holdings in shares of Corbus Pharmaceuticals by 3.0% during the 3rd quarter. Morgan Stanley now owns 2,669,794 shares of the biopharmaceutical company’s stock worth $2,723,000 after buying an additional 77,680 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Corbus Pharmaceuticals by 8.7% during the 3rd quarter. BlackRock Inc. now owns 2,566,443 shares of the biopharmaceutical company’s stock worth $2,618,000 after buying an additional 204,372 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Corbus Pharmaceuticals by 2.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,386,108 shares of the biopharmaceutical company’s stock worth $1,413,000 after buying an additional 28,659 shares in the last quarter. 35.61% of the stock is owned by institutional investors and hedge funds.

Corbus Pharmaceuticals Company Profile (Get Rating)

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases.

Featured Articles

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.